Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gen Hirano
Irinotecan Monotherapy as Third-Line or Later Treatment in Advanced Gastric Cancer
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
A Double‐blind, Randomized, Multicenter Phase 3 Study of Palonosetron vs Granisetron Combined With Dexamethasone and Fosaprepitant to Prevent Chemotherapy‐induced Nausea and Vomiting in Patients With Breast Cancer Receiving Anthracycline and Cyclophosphamide
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
Related publications
Association Between UGT1A1 Gene Polymorphism and Safety and Efficacy of Irinotecan Monotherapy as the Third-Line Treatment for Advanced Gastric Cancer
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
Efficacy of Irinotecan as Third-Line Chemotherapy for Unresectable or Recurrent Gastric Cancer
In Vivo
Biochemistry
Medicine
Genetics
Pharmacology
Molecular Biology
Safety and Continuity of Second- And Third-Line Therapy With Paclitaxel or Irinotecan for Advanced and Recurrent Gastric Cancer
Molecular and Clinical Oncology
Cancer Research
Oncology
ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment for Metastatic Non-Small Cell Lung Cancer
Annals of Oncology
Medicine
Oncology
Hematology
Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
Cancer Research and Treatment
Cancer Research
Oncology
Cetuximab and Irinotecan as Third-Line Therapy in Advanced Colorectal Cancer Patients: A Single Centre Phase II Trial
British Journal of Cancer
Cancer Research
Oncology
Prognostic Factors of Second and Third Line Chemotherapy Using 5-Fu With Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
Cancer Research and Treatment
Cancer Research
Oncology
Weekly Paclitaxel as Second-Line Chemotherapy for Advanced or Recurrent Gastric Cancer
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
Phase II Study on the Combination of Irinotecan Plus Cisplatin as a Second-Line Therapy in Patients With Advanced or Recurrent Gastric Cancer
Molecular and Clinical Oncology
Cancer Research
Oncology
